|
Title
|
Credit (Amnt/Type)
|
Est.Time
|
Expires
|
|
nab-Paclitaxel Improves Overall Response Rate, Reduces Neuropathy in Patients with Advanced Non-Small-Cell Lung Cancer Regardless of Histology; Elderly Also Benefit
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
0.50 hours
|
November 20, 2013
|
|
Afatinib 'Clinically Relevant' First-Line Treatment Option for EGFR-Mutation Positive Lung Adenocarcinoma
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
0.50 hours
|
November 20, 2013
|
|
An Update: Radiation or Surgery for Prostate Cancer
|
1.00
/
AMA PRA Category 1 Credit(s)TM
|
1 hour
|
August 31, 2013
|
|
Beyond Pituitary Surgery: Discussions on Cushing's Disease
|
1.75
/
AMA PRA Category 1 Credit(s)TM
|
1 hour 45 minutes
|
June 25, 2014
|
|
Case 1: A 68-Year-Old African-American Woman With Newly Diagnosed NSCLC
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
30 minutes
|
May 20, 2014
|
|
Case 2: A 60-Year-Old African-American Woman With NSCLC Refractory to First-Line Treatment
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
30 minutes
|
May 20, 2014
|
|
Case 3: A 68-Year-Old African-American Woman With NSCLC Requiring Maintenance Therapy
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
30 minutes
|
June 30, 2014
|
|
Case 4: A 68-Year-Old African-American Man with NSCLC and an Enlarging Solitary Pulmonary Nodule
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
30 minutes
|
June 30, 2014
|
|
Crizotinib Benefits in NSCLC Explored, Including in Patients with ROS1 Gene Rearrangement and with Ablative Local Therapy
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
0.50 hours
|
November 20, 2013
|
|
Feasibility, Cost, Potential Impact of Genomic Testing for Lung Cancer in the Clinic
|
0.50
/
AMA PRA Category 1 Credit(s)TM
|
0.50 hours
|
November 20, 2013
|